Follicle-stimulating hormone, interleukin-1, and bone density in adult women.
Recent studies have indicated that follicle-stimulating hormone (FSH) promotes bone loss. The present study tested the hypothesis that FSH enhances the activity of bone-resorbing cytokines [interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, and IL-6], either by inducing their secretion or by altering their receptor expression. Thirty-six women between the ages of 20 and 50 were assessed for bone mineral density (BMD), reproductive hormone, cytokine ligand and soluble receptor concentrations, and surface expression of cytokine receptors on monocytes. In addition, isolated mononuclear cells were incubated in vitro with exogenous FSH. Univariate regression analyses indicated that BMD was inversely related to serum FSH (r = -0.29 to -0.51, P = 0.03-0.001, depending upon the skeletal site). Physical activity and body composition were also identified as significant factors by multiple regressions. Exogenous FSH induced isolated cells to secrete IL-1beta, TNF-alpha, and IL-6 in proportion to the surface expression of FSH receptors on the monocytes. Endogenous (serum) FSH concentrations correlated with the circulating concentrations of these cytokines. None of these individual cytokines was related to BMD, but the IL-1beta to IL-1 receptor antagonist (IL-1Ra) ratio was inversely related to BMD (r = -0.53, P = 0.002) in all but the most physically active women, who had significantly lower expression of IL-1 type I receptors relative to type II (decoy receptors, P = 0.01). Physical activity also correlated positively with secretion of inhibitory soluble IL-1 receptors (r = 0.53, P = 0.003). Moreover, IL-1Ra correlated strongly with percent body fat (r = 0.66, P < 0.0001). These results indicate that BMD is related to FSH concentration, physical activity, and body composition. Although each of these factors likely has direct effects on bone, the present study suggests that each may also influence BMD by modulating the activity of the osteoresorptive cytokine IL-1beta.
Cannon
Joseph G
JG
School of Allied Health Sciences, Medical College of Georgia, Augusta, GA 30912, USA. jcannon@mcg.edu
Cortez-Cooper
Miriam
M
Meaders
Eric
E
Stallings
Judith
J
Haddow
Sara
S
Kraj
Barbara
B
Sloan
Gloria
G
Mulloy
Anthony
A
D000328:Adult; D000375:Aging / Q000502:physiology*; D001823:Body Composition; D015519:Bone Density / Q000502:physiology*; D002478:Cells, Cultured; D004958:Estradiol / Q000097:blood; D005260:Female; D005434:Flow Cytometry; D043373:Follicle Stimulating Hormone, Human / Q000097:blood* / Q000494:pharmacology; D005498:Follicular Phase / Q000502:physiology*; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000378:metabolism; D053583:Interleukin-1beta / Q000097:blood* / Q000378:metabolism; D020738:Leptin / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D009000:Monocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D009043:Motor Activity; D017472:Receptors, Interleukin-1 / Q000378:metabolism; D012044:Regression Analysis; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D055815:Young Adult
D043373:Follicle Stimulating Hormone, Human; D053590:Interleukin 1 Receptor Antagonist Protein; D053583:Interleukin-1beta; D020738:Leptin; D017472:Receptors, Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D004958:Estradiol; D007986:Luteinizing Hormone